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Abstract
Background: The efficacy of ginsenoside treatment on cognitive decline in individuals with Alzheimer’s disease
(AD) has yet to be investigated. In this protocal, we conducted a systematic review to evaluate the effect of
ginsenosides on cognitive deficits in experimental rodent AD models.
Methods: We identified eligible studies by searching seven electronic databases spanning from January 1980 to
October 2014. We assessed the study quality, evaluated the efficacy of ginsenoside treatment, and performed a stratified
meta-analysis and meta-regression analysis to assess the influence of the study design on ginsenoside efficacy.
Results: Twelve studies fulfilled our inclusion criteria from a total of 283 publications. The overall methodological quality
of these studies was poor. The meta-analysis revealed that ginsenosides have a statistically significant positive effect on
cognitive performance in experimental AD models. The stratified analysis revealed that ginsenoside Rg1 had the greatest
effect on acquisition and retention memory in AD models. The effect size was significantly higher for both acquisition
and retention memory in studies that used female animals compared with male animals.
Conclusions: We conclude that ginsenosides might reduce cognitive deficits in AD models. However, additional well-
designed and well-reported animal studies are needed to inform further clinical investigations.
Background
Alzheimer’s disease (AD), the incidence of which is rap-
idly increasing worldwide, leads to death within 3 to
9 years after diagnosis. It has been estimated that the
number of individuals living to 100 years or more will
increase by over 200 % and that the number of individ-
uals surviving to 90–95 years will double between 2000
and 2020 [1]. One of the most significant disabilities as-
sociated with AD is cognitive impairment [2]. This im-
pairment interferes with work, relationships, leisure, and
activities of daily living and exacts a personal and eco-
nomic cost that is difficult to quantify. In addition, cogni-
tive impairment in AD is associated with a significant
social burden and time commitment on the caregiver [3].
AD is characterized by three neuropathological hall-
marks: neuronal loss, senile plaques (SPs), and
neurofibrillary tangles (NFTs) [4, 5]. SPs predominantly
consist of extracellular amyloid β peptide (Aβ), which is
the key protein that induces neuronal damage and apop-
tosis in AD patients [6, 7]. NFTs are formed by intra-
neuronal aggregation of hyperphosphorylated tau [8].
Few therapeutic options to prevent or alleviate cognitive
deficits in AD exist [9].
Ginseng, the root of Panax ginseng C.A. Meyer, is a
traditional medicinal herb that has been applied widely
in Asia for the treatment of aging and memory deterior-
ation [10]. Ginsenosides such as ginsenoside Rg, ginse-
noside Rb, and ginsenoside Re are the most important
pharmacologically active ingredients in ginseng [11].
Ginsenosides are a class of tetracyclic triterpene glyco-
sides (also known as saponins) [12] that are widely used
in herbal medicine and have been shown to attenuate
cognitive impairment and improve behavioral symptoms
in humans [13]. Recent studies have demonstrated that
the long-term consumption of ginsenoside Rg1 improves
cognitive performance, decreases the levels of Aβ1–42 pro-
tein in the hippocampus of aged senescence-accelerated
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mouse prone 8 (SAMP8) [14], decreases the accumulation
of NFTs [15], increases the extracellular secretion of sol-
uble amyloid precursor protein α (sAPPα), and enhances
α-secretase activity [16]. Rb1 protects neurons against
Aβ1–42-induced neurotoxicity and tau hyperphosphoryla-
tion [17]. Furthermore, ginsenoside Rh2 reduces senile
plaques and plays an important role in neuronal differenti-
ation [18]. Ginsenoside Rd has been shown to alleviate in-
flammation and alleviate cognitive deficits [19].
The need to conduct systematic reviews of animal ex-
periments, which can provide evidence for the potential
translational value of animal models to human disease,
has been highlighted [20]. Systematic reviews and meta-
analyses of animal studies contribute to the modeling of
clinically relevant problems; in particular, such reviews
allow decisions regarding the design and conduct of sub-
sequent clinical trials to be based on all existing evi-
dence synthesized in an unbiased manner. Moreover,
systematic reviews permit a more objective appraisal of
evidence than is allowed by the traditional narrative-
style reviews that are more commonly associated with
animal research [21]. However, there are few systematic
randomized trials and observational studies that have ex-
plored the effect of ginsenosides on cognition in humans
with AD. Therefore, a meta-analysis was conducted to
evaluate the efficacy of ginsenosides for the treatment of
cognitive impairment in experimental animal models of
AD and explore the impact of the study design and qual-
ity on the reported outcomes.
Methods
Literature search
In October 2014, seven electronic databases (PubMed,
Web of Science, MEDLINE, Embase, Google Scholar,
CNKI, and Wanfang) were searched using the terms
“Alzheimer’s disease” (or “dementia”, “Alzheimer disease”,
“Alzheimer”, “Alzheimer’s”, “Alzheimers”) and “ginseno-
side” (or “ginseng, “ginseng saponin”). All the searches
were limited to literature published between January 1980
and October 2014. This systematic review was limited to
the results of animal studies. The reference lists from rele-
vant publications were used to identify further relevant re-
search articles and reviews. Each study had to meet
several inclusion criteria (Table 1) to be included in this
meta-analysis. To determine their eligibility for inclusion,
two investigators (Chenxia Sheng and Weijun Peng)
assessed the titles and abstracts of identified articles,
and obtained copies of the articles to review the study
design and methodology for studies that administered
ginsenoside and measured cognitive, behavioral, and
motor problems in AD model rodents. Disagreements
among the investigators were resolved by consensus
following a discussion.
Data extraction
Two investigators extracted information about the stud-
ies, including the species; sample size; type of AD model;
main experimental groups; type of anesthetic agent; sub-
stances used as experimental and control treatments; the
dose, method, and timing of ginsenoside administration;
and the time of the outcome assessment.
The Morris water maze (MWM) was used to assess
cognition in all the studies included in the analysis. If
cognition was assessed several times in the study, then
only the final assessment was included in the analysis.
For cases in which the data were expressed graphically,
the investigators attempted to obtain numerical values
from the study authors; if these values were not avail-
able, then digital ruler software was used to estimate the
numerical values from the graphs. For cases in which
the data were missing, the investigators contacted the
authors and requested the additional information. If the
required data were not available, then the study was ex-
cluded from the analysis. If one study examined different
animal models of AD or ginsenoside doses, then these
models or doses were analyzed as separate studies.
Methodological quality
The methodological quality of the studies was assessed
based on a checklist modified from the Collaborative
Approach to Meta-Analysis and Review of Animal Data
Table 1 Criteria for study inclusion/exclusion
Inclusion criteria Exclusion criteria
(1) Ginsenoside were administered. (1) Ginsenoside were not administered.
(2) Experimental AD was induced in rodents (i.e., rats or mice). (2) Other types of animals (e.g., sheep, cats, and dogs) were used.
(3) AD treatment group was treated with a pharmacological agent, and a control
group was administered a placebo after injury.
(3) Treatment group was administered another neuroprotective
agent in addition to ginsenoside.
(4) Cognitive function was measured by the MWM. (4) Treatment group was administered another Chinese
Traditional medicine in addition to ginsenoside.
(5) Article was published in English or Chinese language. (5) Only biochemical or physiological outcomes of treatment
efficacy were assessed.
(6) No control group was used. (8) Duplicate publications.
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from Experimental Studies (CAMARADES), as previ-
ously described [22] with minor modifications. The
modified CAMARADES included randomization of sub-
jects into treatment groups instead of blinded induction
of ischemia (allocation concealment) [23]. One point
was tallied for written evidence of each of the follow-
ing criteria: peer-reviewed publication; randomization
of subjects into treatment groups; assessment of
dose–response relationship; blind assessment of be-
havioral outcomes; monitoring of physiological param-
eters, such as body temperature; calculation of the
sample size necessary to achieve sufficient power; state-
ment of compliance with animal welfare regulations;
avoidance of anesthetic agents with marked intrinsic neu-
roprotective properties (e.g., ketamine); statement of po-
tential conflicts of interest; and use of a suitable animal
model (Table 2).
The study quality also was assessed with secondary
criteria as previously described [24] (Table 3). These cri-
teria included study characteristics such as the age, spe-
cies, and sex of the animals used; the duration of
supplementation; and the dose(s) of ginsenoside. These
criteria also included an assessment of the internal valid-
ity of the study, i.e., performance bias (differences in care
provided?); exclusion bias (differences in withdrawal
from studies?); detection bias (differences in outcome
measurements?); and selection bias (differences in allo-
cation to comparison groups?), as well as an assessment
of the external validity of the population, intervention,
and outcome.
Statistical analysis
All statistical analyses were conducted in accordance
with the Cochrane Handbook for Systematic Reviews of
Interventions. For each outcome measure in each study,
the standardized mean difference (SMD; equal to the dif-
ference in the mean outcome between the groups di-
vided by the standard deviation of the outcomes among
the participants, which was reported in units of standard
deviation) was calculated, which allows data measured
on different scales to be merged. Despite the anticipated
heterogeneity, the individual SMDs were pooled when-
ever possible to obtain an overall SMD and 95 % confi-
dence intervals (CI).
Within- and between-study heterogeneity or variation
was assessed using Cochran’s Q-statistic. A significant
Q-statistic (i.e., p < 0.10) indicated heterogeneity among
studies. Heterogeneity also was assessed using the metric
of Cochran’s Q-statistic, I2 values of 25, 50 and 75 % cor-
respond to low, medium and high levels of heterogen-
eity, respectively; values ≤ 50 % indicated an acceptable
degree of heterogeneity between studies [25].
The presence of small-study effects was investigated
with funnel plots and Egger tests. A p < 0.10 on the
Egger test indicated the presence of small-study ef-
fects. For studies comparing different doses or timing
of drug administration to a single control group, the
data from all experimental groups were pooled to
compare with the control group. The pooled effect
size was estimated using fixed- and random-effects
models. When there was heterogeneity among studies,
the pooled effect size was estimated using a random-
effects model.
Both biological and methodological characteristics were
examined in an attempt to explain the possible causes of
heterogeneity (i.e., the possible causes modifying the out-
come) among the studies. Stratified analyses were per-
formed with experiments grouped according to the
following characteristics: species and sex of the animals;
anesthetic method; type and dose of ginsenoside; study
quality; and the route of drug delivery. The difference be-
tween the groups was assessed by partitioning the hetero-
geneity and using the X2 distribution with n-1 degrees of
freedom (df), where n equals the number of groups. To ad-
just the significance levels for multiple comparisons, we
used a Bonferroni correction [26] [declared significance =
1 − (1 − denoted significance)^(1/number of comparisons)],
yielding critical p-values of 0.00215 for the acquisition
memory and 0.00394 for the retention memory.
Finally, the impact of several variables (i.e., species and
sex of the animals; anesthetic method; type and dose of
ginsenoside; study quality; and the route of drug deliv-
ery) on the efficacy of ginsenoside was assessed using
meta-regression when substantial or considerable het-
erogeneity existed.
All statistical analyses were performed using Stata soft-
ware (version 13.0, College Station, Texas, USA) and Re-
view Manager (version 5.3).
Results
Study inclusion
A total of 281 publications were identified, of which 13
met our inclusion criteria [18, 27–38]. Of these 13 publica-
tions, one [18] was excluded from further analysis because
too few data were available to assess in the meta-analysis.
Therefore, this meta-analysis is based on 12 studies, which
included 24 comparisons of acquisition memory and 13
comparisons of retention memory (Fig. 1).
Study characteristics
Of the 12 included studies (Table 4), four were published
in Chinese academic journals and 8 were published in
English academic journals. The Aβ-induced AD model was
the most frequently used animal model of AD [30–33, 35,
37]. Of the 12 studies, four used non-transgenic mice
[27, 31, 35, 37], 4 used Sprague–Dawley rats [28–30, 36],
and four used Wistar rats [32–34, 38]. Six studies used
male animals only [27–30, 32, 36], and three studies used
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Table 2 Characteristics of included studies












chronic restraint stress (CRS) Control r(n = 15) Ig Immediately after injury chloral
hydrate
8 weeks
CRS + distilled water (n = 15)
CRS +2.0 mg/kg Rg1 (n = 15)
CRS +5.0 mg Rg1 /kg r(n = 15)
Bombi Lee et al.
2013
Male SD rats LPS injected into the bilateral
lateral cerebral ventricle
LPS-injected plus saline (n = 6) Ip Immediately after injury pentobarbital 3 weeks
LPS-injected plus 10 mg/kg Rg3 (n = 6)
LPS-injected plus 20 mg/kg Rg3 (n = 6)
LPS-injected plus 30 mg/kg Rg3 (n = 6)
Song XY et al.
2013
Male SD rats OKA injected into the right
lateral cerebral ventricle





OKA-injected plus 5 mg/kg Rg1 (n = 12)
OKA-injected plus 10 mg/kg Rg1 (n = 12)
OKA-injected plus 20 mg/kg Rg1 (n = 12)
Quan QK et al.
2013
Male SD rats Aβ1–42 injected into Both
Hippocampal CA1 regions
Aβ1–42 injected plus normal saline (n=10) Ip 5 days after Aβ1–42 injected chloral
hydrate
4 weeks
Aβ1–42 injected plus 10 mg/kg Rg1 (n = 10)




Oral AlCl3 in drinking water Al exposure plus distilled water (n = 8) Ig 6 month after AlCl3 oraled pentobarbital 4 months
Al exposure plus 20 mg/kg Rb1 (n = 8)
Wang YL et al.
2011
Male Wistar rats Aβ1-40 into the right lateral
cerebral ventricle
Aβ1-42 plus saline (n = 10) Ip 2 weeks after AlCl3 orale not clear 4 weeks
A1-42 plus 10 mg/kg Rg2 (n = 10)






OVX, D-gal plus vehicle Ip Immediately after injury chloral
hydrate
6 weeks
OVX, D-gal plus 5 mg/kg Rg1 (n = 8)
OVX, D-gal plus 10 mg/kg Rg1 (n = 8)
OVX, D-gal plus 20 mg/kg Rg1 (n = 8)
Chu SH et al. 2014 Wistar rats Streptozotocin (STZ) injected
into the bilateral lateral cerebral
ventricle
STZ plus physiological saline (n = 12) Ig 2 days after STZ injected not clear 4 weeks
STZ plus 5 mg/kg Rg5 (n = 12)
STZ plus 10 mg/kg Rg5 (n = 12)
STZ plus 20 mg/kg Rg5 (n = 12)
Zhou LP et al. 2011 Female C57BL/6
mice
Ovariectomized (OVX) & Aβ25-35
injected into the lateral cerebral
ventricle
OVX, Aβ 25–35 plus Rg1 10 mg/kg (n=10) Ip 10 days later chloral
hydrate
14 days




Aβ25–35 injected into the lateral
cerebral ventricle
Aβ25-35 plus physiological saline (n = 10) Ip 1 days after Aβ25-35 injected diethyl ether 10 days
Aβ25-35 plus 5 mg/kg Rg5 (n = 10)
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10 mg/kg Rg1 (n = 15)
Zang Y et al. 2010 Male & female
Wistar rats
Aβ25–35 injected into Both
Hippocampal regions





Aβ25-35 plus 3 mg/kg Rg2 (n = 12)
Aβ25-35 plus 6 mg/kg Rg2 (n = 12)
Aβ25-35 plus 12 mg/kg Rg2 (n = 12)


















Fig. 1 Flow diagram of study search process
Table 3 The CAMARADES quality items
Study ➀ ➁ ➂ ➃ ➄ ➅ ➆ ➇ ➈ ➉ Quality score
Wang YC et al. 2014 √ √ √ √ √ √ √ 7
Bombi Lee et al. 2013 √ √ √ √ √ √ √ √ 8
Song XY et al. 2013 √ √ √ √ √ √ 6
Quan QK et al. 2013 √ √ √ √ √ √ 6
Zhao HH et al. 2012 √ √ √ √ √ √ 6
Wang YL et al. 2010 √ √ √ ? √ 4
Zhang X et al. 2012 √ √ √ √ √ √ √ √ 8
Chu SH et al. 2014 √ √ √ ? √ 4
Zhou LP et al. 2011 √ √ √ √ 4
Wang XY et al. 2001 √ √ √ √ √ √ 6
Wu W et al. 2011 √ √ √ √ 4
Zang Y et al. 2010 √ √ √ √ √ 5
(1) peer reviewed publication; (2) presence of randomization of subjects into treatment groups; (3) assessment of dose–response relationship; (4) blinded
assessment of behavioural outcome; (5) monitoring of physiological parameters such as body temperature; (6) calculation of necessary sample size to achieve
sufficient power; (7) statement of compliance with animal welfare regulations; (8) avoidance of anaesthetic agents with marked intrinsic neuroprotective
properties (e.g., ketamine); (9) statement of potential conflict of interests; (10) use of a suitable animal model
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female animals only [31, 33, 35]. One study [38] used equal
numbers of male and female animals. Two studies [34, 37]
did not report the sex of the animals used. Across all stud-
ies, ginsenoside Rg1, ginsenoside Rg2, ginsenoside Rg3, gin-
senoside Rg5, and ginsenoside Rb1 were administered as
experimental treatments in doses of 1, 2, 3, 4, 5, 6, 9, 10, 20,
or 30 mg/kg/day via either oral gavage or intraperitoneal in-
jection. All studies used the MWM to assess cognitive
function.
Methodological quality of studies
A large variety of tools to assess the quality of animal
studies is currently used, but none of these tools focus
on internal validity only. Most instruments assess the
reporting quality and internal and external validity sim-
ultaneously even though the consequences associated
with poor reporting, the risk of bias, or the
generalizability of the results are different [39].
Therefore, two tools were used to assess the quality of
each study using the CAMARADES checklist. Overall,
the median quality score for the 12 included studies was
poor (5.29; interquartile range: 5–6), with scores ranging
from 4 to 8. No study received a score of 0 or 10. Three
studies received scores that indicated high quality [27,
28, 33], and these 3 studies reported the monitoring of
physiological parameters during surgical procedures.
One study [34] did not report the randomization of ani-
mals into treatment groups. Three studies [31, 32, 35,
36] assessed dose–response relationships. Three stud-
ies [30, 31, 33] stated no potential conflict of inter-
ests. Only one study [28] contained a statement that
outcome measures were assessed by experimenters
who were blind to the treatment condition. Moreover,
no study described the sample size calculation to confirm
that sufficient power had been achieved. The median qual-
ity score indicated that 17.5 out of 21 of the secondary
























Research question specified and clear? √ √ √ √ √ √ √ √ √ √ √ √
Outcome measures relevant for AD research √ √ √ √ √ √ √ √ √ √ √ √
Are the characteristics of study population clear?
Species √ √ √ √ √ √ √ √ √ √ √ √
Background/generation √ √ √ √ √ √ √ √ √ √ √ √
Sex (and distribution) √ √ √ √ √ N √ N √ √ √ N
Age N √ √ √ √ √ √ √ √ √ √ √
Presence and correct control group? √ √ √ √ √ √ √ √ √ √ √ √
Where the groups similar at baseline (if not
randomized think of weight and sex etc.)?
√ √ √ √ √ N √ N √ ? √ N
Is the experiment randomized? √ √ √ √ √ N √ N √ √ √ √
Kind of supplement mentioned (ginsenoside)? √ √ √ √ √ √ √ √ √ √ √ √
Age when supplementation started mentioned? √ √ √ √ √ √ √ √ √ √ √ √
Duration of supplementation clear and specified? √ √ √ √ √ √ √ √ √ √ √ √
Amount of ginsenoside mentioned √ √ √ √ √ √ √ √ √ √ √ √
Administration route specified √ √ √ √ √ √ √ √ √ √ √ √
Is the timing of the supplementation during the day
specified and similar in both groups?
√ √ √ √ √ √ √ √ √ √ √ √
Methods used for outcome assessment the same in
both groups?
√ √ √ √ √ √ √ √ √ √ √ √
Did report animals who died or were otherwise
removed from the study
N N N N N N N N N N N N
Blinded outcome assessment? N √ N N N N N N N N N N
Was the outcome assessment randomized across the
groups?
N N N N N N N N N N N N
Total number of animals included in statistical
analyses clear?
√ √ √ √ √ √ √ √ √ √ √ √
Age of sacrificing animals mentioned? √ √ √ √ √ √ √ √ √ √ √ √
Quality score (items√) 17 19 18 18 18 15 18 15 18 17 18 18
√ = fulfilling the criterion, no = not fulfilling the criterion, ? = not enough information to determine whether or not the raised criterion is
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criteria had been reported. The lowest score was 15 items
(16.67 %) and the highest score was 19 items (8.33 %). Al-
though treatment blinding and a description of the number
of animals that died or were otherwise removed from the
study are key measures for assessing the quality of studies,
no study reported this information. One study [34] reported
that investigators were blind to the treatment condition
during the outcome assessment, and none of the papers de-
scribed randomizing the order of the outcome assessments
across the groups.
Overall efficacy
For acquisition memory, the global estimated effect of gin-
senosides was −2.14 (95 % CI: −2.69 to −1.79, p < 0.0001)
with significant heterogeneity among studies (X2 = 136.74,
df = 30, p < 0.0001, I2 = 83 %; Fig. 2a). For retention mem-
ory, the global estimated effect of ginsenosides was
2.65 (95 % CI: 1.67 to 3.64, p < 0.0001), with signifi-
cant heterogeneity among studies (X2 = 108.89, df = 12,
p < 0.0001, I2 = 89 %; Fig. 2b).
Stratified meta-analysis
Subgroup analyses were conducted to assess the degree
to which methodological differences between trials
might have systematically influenced the differences ob-
served in the primary treatment outcomes. The overall
summary of each subgroup then can be inspected for
evidence of variation in the effects of the intervention,
which would suggest that the stratifying characteristic is
an important source of heterogeneity and may modify
the treatment efficacy. Current guidelines recommend at
least 10 studies per characteristic for stratifying sub-
groups [40]. The results of the stratified analyses are de-
scribed in Table 5.
First, the protective effects of ginsenoside Rb, ginseno-
side Rg1, ginsenoside Rg2, ginsenoside Rg3, and ginse-
noside Rg5 administration on cognitive performance
were examined. Rg1 treatment had a significantly greater
beneficial effect on acquisition memory and retention
memory (X2 = 29.55, df = 4, p < 0.00001, I2 = 86.5 % and
X2 = 6.15, df = 1, p = 0.001, I2 = 83.7 %, respectively) com-
pared with Rb treatment, Rg2 treatment, Rg3 treatment,
or Rg5 treatment. Next, the efficacy of different doses of
ginsenosides on cognitive performance was analyzed.
For both acquisition and retention memory, significant
beneficial effects were noted for all doses of ginsenosides.
The protective effects of 30 mg or higher doses on acqui-
sition memory were examined to determine whether the
effects of higher doses are greater than those of lower
doses. A 30 mg or higher dose was associated with a
greater beneficial effect than a dose less than 30 mg on ac-
quisition memory; however, no significant differences
among doses were detected (X2 = 11.64, df = 3, p = 0.009,
I2 = 74.2 %). The protective effects at 10 mg or higher
doses on retention memory also were examined to deter-
mine whether the effects of higher doses are greater than
lower doses, and a significant effect was found. A 10 mg
dose was associated with a significantly greater beneficial
outcome compared with a dose less than 10 mg or more
than 10 mg for retention memory (X2 = 12.16, df = 2,
p < 0.002, I2 = 83.5 %; Fig. 3).
The protective effects of species and sex also were ex-
amined. For acquisition memory, although the effect size
was higher in studies that used rat models, no significant
difference was detected between studies that used rat
models or mouse models (X2 = 6.97, df = 1, p = 0.008,
I2 = 85.7 %). However, for retention memory, the effect
size was significantly higher in studies that used rat models
compared with mouse models (X2 = 5.58, df = 1, p = 0.002,
I 2 = 82.1 %). For both acquisition memory and retention
memory, the effect size was significantly higher in
studies that used female animals compared with male
animals (X2 = 16.72, df = 3, p < 0.0008, I2 = 82.5 % and X2 =
7.25, df = 1, p = 0.003, I2 = 72.4 %, respectively; Fig. 4).
Fig. 2 The effects of ginsenosides on (a) acquisition memory and (b) retention memory. The horizontal lines represent the mean estimated effect
size and the 95 % confidence interval (CI) for each comparison. The vertical gray bars represent the 95 % CI of the pooled estimate effect size
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The effect of the anesthetic agent and the route of drug
delivery also were examined. For acquisition memory and
retention memory, although the effect size was higher in
studies that used chloral hydrate anesthesia, no significant
differences among anesthetic agents were detected
(X2 = 7.38, df = 3, p = 0.006, I2 = 53.6 % and X2 = 0.03,
df = 1, p = 0.87, I2 = 0 %, respectively; Fig. 5). For ac-
quisition memory, although the effect size was higher
in studies that used intraperitoneal injection, no sig-
nificant differences in the routes of drug delivery were de-
tected (X2 = 0.17, df = 1, p = 0.68, I2 = 0 %; Fig. 5c). Oral
gavage was associated with a significantly greater beneficial
outcome than intraperitoneal injection for retention mem-
ory (X2 = 9.83, df = 1, p = 0.002, and I2 = 89.8 %; Fig. 5d).
The effect sizes for acquisition and retention memory
also were examined relative to the study quality score.
Significant differences in effect sizes were observed be-
tween lower-scoring and higher-scoring studies for both
acquisition (X2 = 25.03, df = 4, p < 0.00001, I2 = 84.3 %)
and retention (X2 = 29.03, df = 4, p < 0.00001, I2 = 86.2 %)
memory. The effect size for acquisition memory was
maximal for studies with a quality score of 4 (−4.05,
Table 5 The results of stratified meta-analysis
Subgroups Acquisition memory Retention memory
Studies Participants Effect size, 95 % CI Studies Participants Effect size , 95 % CI
Gensenosides
Rb 2 56 −2.21 [−2.90, −1.53] P < 0.00001
Rg1 13 290 −2.86 [−3.83, −1.90] 9 200 3.52 [1.95, 5.09] P = 0.01
Rg2 3 72 −1.31 [−1.82, −0.79] 4 88 1.40 [−0.84, 1.97]
Rg3 3 36 −2.56 [−4.42, −0.71]
Rg5 3 72 −0.46 [−0.96, 0.04]
Dose
1–9 mg 9 216 −1.287 [−1.92, −0.62] P = 0.009 7 172 1.17 [0.42, 1.93] P = 0.002
10 mg 9 206 −2.54 [−3.49, −1.59] 3 60 6.54 [1.97, 11.1]
20 mg 5 92 −2.90 [−4.51, −1.28] 3 56 4.30 [2.22, 6.37]
30 mg 1 12 −4.81 [−7.41, 2.20]
Animal species
Mouse 6 136 −1.21 [−1.87, −0.55] P = 0.008 4 96 1.35 [0.34,2.35] P = 0.002
Rat 18 390 −2.52 [−3.24, −1.80] 9 192 3.52 [2.02,5.01]
Gender
Male 11 258 −2.65 [−3.66, −1.63] P = 0.0008 5 256 3.22 [1.66, 6.26] P = 0.003
Female 5 84 −3.42 [−4.84, −2.00] 5 84 3.78 [1.38, 6.10]
Mixed 3 72 −1.31 [−1.82, −0.79] 3 73 1.22 [0.70, 1.73]
Unclear 5 112 −0.86 [−1.46, −0.26]
Anesthetic agent
Pentobarbital 4 52 −2.22 [−3.40, −1.05] P = 0.06 1 16 2.53 [1.13, 3.94] P = 0.87
Chloral hydrate 14 322 −2.66 [−3.52, −1.80] 12 272 2.68 [1.63, 3.72]
Ether 2 40 −1.58 [−2.32, −0.85]
Unclear 4 112 −0.95 [−1.96, 0.06]
Drug delivery
ip 17 366 −2.23 [−2.87, −1.58] P = 0.68 9 200 1.61 [0.73, 2.49] P = 0.002
0r 7 160 −1.95 [−3.09, −0.81] 4 88 4.50 [2.92, 6.08]
Study quality
4 2 50 −4.05 [−8.02, −0.08] P < 0.00001 1 20 2.36 [1.16, 3.56] P < 0.001
5 3 72 −1.31 [−1.82, −0.79] 6 132 1.22 [2.92, 6.08]
6 11 260 −1.90 [−2.63, −1.17] 4 88 4.50 [2.92, 6.08]
7 2 60 −0.36 [−0.87, 0.15] 6 124 0.52 [0.00, 1.03]
8 6 84 −3.66 [−5.20, −2.13] 3 48 5.98 [−0.63, 12.59]
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Fig. 4 The effect size for acquisition memory is stratified by (a) species; and (b) sex. The effect size for retention memory is stratified by (c)
species; and (d) sex. The gray bands represent the 95 % CI for the global estimated effect size
Fig. 3 The effect size for acquisition memory is stratified by (a) the type of Ginsenosides; and (b) the dose. The effect size for retention memory
is stratified by (c) the type of Ginsenosides; and (d) the dose. The gray bands represent the 95 % CI for the global estimated effect size
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95 % CI: −8.02 to −0.08; Fig. 6a), and the effect size for
retention memory was higher for studies with a quality
score of 8 (5.98, 95 % CI: −0.63 to 12.59; Fig. 6b) than
those with lower scores.
Meta-regression analyses
Meta-regression is an extension of the subgroup analysis
that allows for the investigation of the effect of multiple
factors simultaneously. The outcome variable is the effect
estimate, and the explanatory variables are the study char-
acteristics that might influence the effect size, which are
often called the “potential effect modifiers” or covariates.
To further explore the heterogeneity among studies,
meta-regression was conducted for the acquisition and
retention memory results. For retention memory, the
species and sex of the animals, anesthetic method, type
and dose of ginsenoside, study quality score, and route
of drug delivery explained 49.03 % of the heterogeneity.
For acquisition memory, heterogeneity was independ-
ent of these factors.
Publication bias
Finally, the presence of small-study effects, which may
contribute to publication bias, were identified. Funnel
plots showed an asymmetry for both the acquisition
(Fig. 7a) and retention memory (Fig. 7b) data, which
provides evidence for small-study effects (Egger regres-
sion, p < 0.0001 and p < 0.001, respectively).
Fig. 6 The effect size is stratified by study quality score (a) for acquisition memory and (b) for retention memory. The gray bands represent the
95 % CI for the global estimated effect size. The gray bands represent the 95 % CI for the global estimated effect size
Fig. 5 The effect size for acquisition memory is stratified by (a) anesthetic agent; and (b) route of delivery. The effect size for retention memory is
stratified by (c) anesthetic agent; and (d) route of delivery. The gray bands represent the 95 % CI for the global estimated effect size
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Possible drug protection mechanism analysis
All studies that were included in the analysis assessed the
biological mechanisms of ginsenoside activity. Across stud-
ies, the neuroprotective effect of ginsenoside was attributed
primarily to anti-inflammatory activity [28, 32, 34]. Ginse-
noside was reported to promote the non-amyloidgenic
cleavage of beta-amyloid precursor protein (APP) [18], at-
tenuate Aβ formation [29], decrease Aβ levels, attenuate
hippocampal histopathological abnormalities [30], prevent
tau hyperphosphorylation via the regulation of p-GSK3
and serine/threonine-specific protein phosphatase 2A
levels [31], activate the endoplasmic reticulum signaling
pathway, inhibit the activity of acetylcholinesterase [37],
and upregulate the expression of nerve growth factor [36].
Discussion
Many animal experiments are performed to inform hu-
man health, and may play an important role in the iden-
tification and development of drugs, medical devices,
and surgical procedures; risk assessments for safe human
exposures; and increasing biological knowledge. It would
seem rational to critically review the existing relevant
animal experiments before new animal experiments and,
in particular, clinical trials in humans are performed.
Systematic reviews and meta-analyses are suitable tools
to summarize the current evidence on a given subject,
and therefore directly support the ‘three Rs’ (i.e., replace-
ment, reduction, and refinement) by, for example, pre-
venting the unnecessary duplication of animal studies.
Systematic reviews and meta-analyses play an important
role in physics, the social sciences, and medicine [41].
The results of this systematic review and meta-analysis
show that ginsenoside provides neuroprotective effects
in terms of improving cognitive outcomes in AD. Ginse-
noside Rg1 exhibited the highest protective effect on
both acquisition and retention memory. The species and
sex of the animals, the type and dose of ginsenoside, and
the study quality all had significant impacts on the effect
Fig. 7 Funnel plot for acquisition memory (a) and retention memory (b)
Sheng et al. BMC Complementary and Alternative Medicine  (2015) 15:386 Page 12 of 15
size. In contrast, the route of drug delivery and the
anesthetic method had no significant effects on the out-
comes. Our analysis also suggests that some aspects of
the original study design had an impact on the study
outcome. First, the effect size was higher in rat studies
than in mouse studies, which suggests that different spe-
cies may react differently to ginsenoside. Second, the
route of administration and dosage of ginsenoside also
affected the outcome [42]. The protective effect on ac-
quisition memory was better with doses of 30 mg or
higher (although not significantly) and the protective ef-
fect on retention memory was better with doses of
10 mg. These results are not consistent with the dose-
linear response curve described previously, in which
higher doses yielded a greater response [43]. The effect
size probably was overstated in studies that administered
lower doses.
The methodological quality of the studies was assessed
according to standards previously described for the pre-
clinical development of neuroprotective drugs with
minor modifications [22, 24]. In general, the quality of
the included studies was poor. For example, only one
study reported that investigators were blind to the treat-
ment condition during the behavioral assessments.
Treatment blinding is recommended in open-label trials
to reduce bias. If patients, clinicians, or assessors are
aware of the treatment assignment, then this knowledge
may influence the reporting or measurement of the out-
come and introduce bias [44]. Moreover, all the studies
failed to report the calculation of the sample size neces-
sary to achieve sufficient power, which is crucial to judge
the efficacy of a new therapy or drug [45]. Unfortunately,
the reporting of sample size elements specific to these
random trials remains below that necessary for transpar-
ent reporting. The authors should calculate the sample
size during the planning phase of the study to assess the
accuracy of the a priori estimates and aid the design of
future trials. In addition, journal editors and peer re-
viewers should implement stricter requirements for au-
thors to follow CONSORT recommendations [46]. All
studies failed to report animals that died or were other-
wise removed from the study. As these events may have
been due to medication side effects, this information is
important in assessing the use of ginsenoside.
Systematic reviews can use research data from numer-
ous study designs. However, when conducting systematic
reviews of interventions, studies conducted using low
evidentiary designs for evaluating real-world efficacy are
generally not appropriate for inclusion [47]. In our sys-
tematic review, high quality studies showed a trend to-
ward better acquisition memory outcomes, but studies
with lower quality scores exhibited the highest protective
effect on retention memory. The effect size was probably
overstated in studies with lower quality scores.
Our study has several limitations. First, although we
conducted a thorough literature search, we did not con-
duct a search of older data that has not been indexed in
an electronic/online database. Our analysis is based only
on published data or academic dissertation data available
online, most of which showed positive results; therefore,
our study may have missed ‘negative’ results. In addition,
positive results, which are easier to publish, often appear
in journals with higher impact factors than negative re-
sults [48]. The funnel plots and Egger tests suggest the
possibility of a publication bias or other small-study bias,
which is consistent with observations from other sys-
tematic reviews of animal studies [49]. Publication bias,
which is considered a potential threat to the validity of
all systematic reviews that include experimental studies,
may have led to an overestimation of the protective ef-
fect of ginsenoside in our study. Second, we focused only
on the effect of ginsenoside on cognitive deficits in AD.
We did not conduct analyses to investigate the effect on
histopathology, such as plaques and tangles, due to in-
sufficient data. Third, due to language barriers, we only
searched databases for articles published in English or
Chinese, and did not search for studies published in
other languages such as Korean. Korea is one of the
main countries that uses ginseng, and therefore we may
have missed some relevant publications. In addition, the
animals used in the included studies were young ro-
dents, which is not consistent with the average age of
humans in the relevant clinical setting of AD. There re-
main some unknown factors that contributed to the het-
erogeneity of the effect size in our study. The number of
preclinical experiments performed each year continues
to increase, and our understanding of the disease mech-
anism is improving. However, the number of novel inter-
ventions that reach the clinic to treat cerebrovascular
diseases continues to fall due to limitations in the trans-
lational paradigm [50]. The standardization of animal
protocols and the systematic review of animal models
that do not currently qualify as predictive modalities for
human responses to drugs and disease are supported by
experts in various fields of science [51]. Therefore, these
limited results may not be adequate for the transition
from animal experiments to human clinical trials. Con-
sequently, prior to making any clinical practice recom-
mendations, high methodological reporting and quality
control experimental studies are needed to better evalu-
ate the impact of this promising pharmacological inter-
vention for AD.
Conclusion
This systematic review and meta-analysis indicates that
treatment with ginsenoside can alleviate cognitive deficits
in experimental animal models of AD. Although some fac-
tors, such as the study quality and a potential publication
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bias, may undermine the validity of these positive findings,
ginsenosides may play a potential neuroprotective role in
AD. However, without rigorous, robust, and detailed pre-
clinical evaluations, novel neuroprotective drugs may prove
to be ineffective when tested in large, time-consuming, and
expensive human clinical trials. Therefore, additional well-
designed and well-reported experimental animal studies
are needed.
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